



Koneksa is the leading digital biomarker company for pharmaceutical and biotechnology industries, doing the R&D to deliver in-clinic quality measures that matter for our clients, for our partners, and for patients

More publications, describing how to apply the V3 framework in real life are needed as these publications build a common language, joint understanding within the scientific community, and therefore propel the field forward.

— **Elena Izmailova**, CSO at Koneksa Health

The Problem



Koneksa [follows](#) DATAcc by DiMe's [systematic review](#) whenever applicable to guide, design and execute sensor-based DHT validation experiments.

The Impact



As evidenced by DATAcc's systematic review, the industry will benefit from seeing more examples of the V3 framework and EVIDENCE checklist in action in an organized and systematic manner. Using these resources will encourage a design and execution of new DHT-based experiments.

The Resources



The systematic review used criteria established by the [V3 Framework](#) and [EVIDENCE checklist](#) to assess the state of the science on analytical validation for connected, mobile, and sensor-based DHTs.

V3

EVIDENCE
✓ Checklist



DATAcc

by DiMe